Folic acid prevents depressive-like behavior induced by chronic corticosterone treatment in mice

Pharmacology Biochemistry and Behavior

Volumn 127, Issue , 2014, Pages 1-6

  Rosa, Priscila B ^a   Ribeiro, Camille M ^a   Bettio, Luis E B ^a   Colla, André ^a   Lieberknecht, Vicente ^a   Moretti, Morgana ^a,b   Rodrigues, Ana Lúcia S ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b REGIONAL UNIVERSITY OF BLUMENAU   (Brazil)

Author keywords

Antidepressant; Corticosterone; Depression; Folic acid; Stress

Indexed keywords

CORTICOSTERONE; FLUOXETINE; FOLIC ACID; ANTIDEPRESSIVE AGENTS;

ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DEPRESSION; FEMALE; GROOMING; IMMOBILITY; LOCOMOTION; MOUSE; NONHUMAN; TAIL SUSPENSION TEST; ANIMALS; CHEMICALLY INDUCED; DRUG ADMINISTRATION SCHEDULE; IMMOBILIZATION; MICE; PSYCHOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTIDEPRESSIVE AGENTS; CORTICOSTERONE; DEPRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLIC ACID; IMMOBILIZATION; MICE; TREATMENT OUTCOME;

EID: 84908509005     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2014.10.003     Document Type: Article

References (50)

1. Abou-Saleh MT, Coppen A. Folic acid and the treatment of depression. J Psychosom Res 2006;61:285-7.
2. Ago Y, Arikawa S, Yata M, Yano K, Abe M, Takuma K, et al. Antidepressant-like effects of the glucocorticoid receptor antagonist RU-43044 are associated with changes in prefrontal dopamine in mouse models of depression. Neuropharmacology 2008;55:1355-63.
3. Ago Y, Yano K, Araki R, Hiramatsu N, Kita Y, Kawasaki T, et al. Metabotropic glutamate 2/3 receptor antagonists improve behavioral and prefrontal dopaminergic alterations in the chronic corticosterone-induced depression model in mice. Neuropharmacology 2013;65:29-38.
4. Brocardo PD, Budni J, Lobato KR, Kaster MP, Rodrigues ALS. Antidepressant-like effect of folic acid: involvement of NMDA receptors and L-arginine-nitric oxide-cyclic guanosine monophosphate pathway. Eur J Pharmacol 2008a;598:37-42.
5. Brocardo PS, Budni J, Kaster MP, Santos AR, Rodrigues AL. Folic acid administration produces an antidepressant-like effect in mice: evidence for the involvement of the serotonergic and noradrenergic systems. Neuropharmacology 2008b;54:464-73.
6. Brocardo PS, Budni J, Lobato KR, Santos AR, Rodrigues AL. Evidence for the involvement of the opioid system in the antidepressant-like effect of folic acid in the mouse forced swimming test. Behav Brain Res 2009;200:122-7.
7. Budni J, Freitas AE, Binfare RW, Rodrigues AL. Role of potassium channels in the antidepressant-like effect of folic acid in the forced swimming test in mice. Pharmacol Biochem Behav 2012a;101:148-54.
8. Budni J, Lobato KR, Binfare RW, Freitas AE, Costa AP, Martin-de-Saavedra MD, et al. Involvement of PI3K, GSK-3beta and PPARgamma in the antidepressant-like effect of folic acid in the forced swimming test in mice. J Psychopharmacol 2012b;26:714-23.
9. Budni J, Zomkowski AD, Engel D, Santos DB, dos Santos AA, Moretti M, et al. Folic acid prevents depressive-like behavior and hippocampal antioxidant imbalance induced by restraint stress in mice. Exp Neurol 2013;240:112-21.
10. Castela E, Archier E, Devaux S, Gallini A, Aractingi S, Cribier B, et al. Topical corticosteroids in plaque psoriasis: a systematic review of efficacy and treatment modalities. J Eur Acad Dermatol Venereol 2012;26(Suppl. 3):36-46.
11. Chen L, Dai J, Wang Z, Zhang H, Huang Y, Zhao Y. Ginseng total saponins reverse corticosterone-induced changes in depression-like behavior and hippocampal plasticity-related proteins by interfering with GSK-3 beta-CREB signaling pathway. Evid Based Complement Alternat Med 2014;2014:506735.
12. Cryan JF, Markou A, Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 2002;23:238-45.
13. Curtis AL, Bethea T, Valentino RJ. Sexually dimorphic responses of the brain norepinephrine systemto stress and corticotropin-releasing factor. Neuropsychopharm2006;31:544-54.
14. Fernandez F, Coomans V, Mormede P, Chaouloff F. Effects of corticosterone ingestion on hippocampal [(3)H]serotonin reuptake in inbred rat strains. Endocr Regul 2001;35:119-26.
15. Gold PW, Chrousos GP. Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. Mol Psychiatry 2002;7:254-75.
16. Gold PW, Licinio J, Wong ML, Chrousos GP. Corticotropin releasing hormone in the pathophysiology of melancholic and atypical depression and in the mechanism of action of antidepressant drugs. Ann N Y Acad Sci 1995;771:716-29.
17. Gregus A, Wintink AJ, Davis AC, Kalynchuk LE. Effect of repeated corticosterone injections and restraint stress on anxiety and depression-like behavior inmale rats. Behav Brain Res 2005;156:105-14.
18. Hammen C. Stress and depression. Annu Rev Clin Psychol 2005;1:293-319.
19. Heim C, Nemeroff CB. The role of childhood trauma in the neurobiology of mood and anxiety disorders: preclinical and clinical studies. Biol Psychiatry 2001;49:1023-39.
20. Howell KR, Kutiyanawalla A, Pillai A. Long-term continuous corticosterone treatment decreases VEGF receptor-2 expression in frontal cortex. PLoS One 2011;6:e20198.
21. Iijima M, Ito A, Kurosu S, Chaki S. Pharmacological characterization of repeated corticosterone injection-induced depression model in rats. Brain Res 2010;1359:75-80.
22. Inoue T, Koyama T. Effects of acute and chronic administration of high-dose corticosterone and dexamethasone on regional brain dopamine and serotonin metabolism in rats. Prog Neuropsychopharmacol Biol Psychiatry 1996;20:147-56.
23. Johnson SA, Fournier NM, Kalynchuk LE. Effect of different doses of corticosterone on depression-like behavior and HPA axis responses to a novel stressor. Behav Brain Res 2006;168:280-8.
24. Juruena MF, Cleare AJ, Pariante CM. The hypothalamic pituitary adrenal axis, glucocorticoid receptor function and relevance to depression. Rev Bras Psiquiatr 2004;26:189-201.
25. Keller J, Flores B, Gomez RG, Solvason HB, Kenna H, Williams GH, et al. Cortisol circadian rhythm alterations in psychotic major depression. Biol Psychiatry 2006;60:275-81.
26. Kronenberg G, Colla M, Endres M. Folic acid, neurodegenerative and neuropsychiatric disease. Curr Mol Med 2009;9:315-23.
27. Le Mevel JC, Abitbol S, Beraud G, Maniey J. Temporal changes in plasma adrenocorticotropin concentration after repeated neurotropic stress in male and female rats. Endocrinology 1979;105:812-7.
28. Manosso LM, Moretti M, Rodrigues AL. Nutritional strategies for dealing with depression. Food Funct 2013;4:1776-93.
29. Moretti M, Freitas AE, Budni J, Fernandes SC, Balen Gde O, Rodrigues AL. Involvement of nitric oxide-cGMP pathway in the antidepressant-like effect of ascorbic acid in the tail suspension test. Behav Brain Res 2011;225:328-33.
30. Moretti M, Colla A, de Oliveira Balen G, dos Santos DB, Budni J, de Freitas AE, et al. Ascorbic acid treatment, similarly to fluoxetine, reverses depressive-like behavior and brain oxidative damage induced by chronic unpredictable stress. J Psychiatr Res 2012;46:331-40.
31. Morris DW, Trivedi MH, Rush AJ. Folate and unipolar depression. J Altern Complement Med 2008;14:277-85.
32. Morris MC, Compas BE, Garber J. Relations among posttraumatic stress disorder, comorbid major depression, and HPA function: a systematic review and meta-analysis. Clin Psychol Rev 2012;32:301-15.
33. Nemeroff CB. The burden of severe depression: a review of diagnostic challenges and treatment alternatives. J Psychiatr Res 2007;41:189-206.
34. Nemeroff CB, Musselman DL, Evans DL. Depression and cardiac disease. Depress Anxiety 1998;1:71-9.
35. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. Neuron 2002;34:13-25.
36. Owen RT. Folate augmentation of antidepressant response. Drugs Today (Barc) 2013;49:791-8.
37. Papakostas GI, Petersen T, Lebowitz BD, Mischoulon D, Ryan JL, Nierenberg AA, et al. The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine. Int J Neuropsychopharmacol 2005;8. [528-528].
38. Papakostas GI, Shelton RC, Zajecka JM, Etemad B, Rickels K, Clain A, et al. L-Methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry 2012;169:1267-74.
39. Piwowarska J, Chimiak A, Matsumoto H, Dziklinska A, Radziwon-Zaleska M, Szelenberger W, et al. Serum cortisol concentration in patients with major depression after treatment with fluoxetine. Psychiatry Res 2012;198:407-11.
40. Reynolds EH. Folic acid, ageing, depression, and dementia. BMJ 2002;324:1512-5.
41. Sarris J, Schoendorfer N, Kavanagh DJ. Major depressive disorder and nutritional medicine: a review of monotherapies and adjuvant treatments. Nutr Rev 2009;67:125-31.
42. Seale JV, Wood SA, Atkinson HC, Bate E, Lightman SL, Ingram CD, et al. Gonadectomy reverses the sexually diergic patterns of circadian and stress-induced hypothalamic-pituitary-adrenal axis activity in male and female rats. J Neuroendocrinol 2004;16:516-24.
43. Sterner EY, Kalynchuk LE. Behavioral and neurobiological consequences of prolonged glucocorticoid exposure in rats: relevance to depression. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:777-90.
44. Steru L, Chermat R, Thierry B, Simon P. The tail suspension test: a newmethod for screening antidepressants in mice. Psychopharmacology (Berl) 1985;85:367-70.
45. Swaab DF, Bao AM, Lucassen PJ. The stress system in the human brain in depression and neurodegeneration. Ageing Res Rev 2005;4:141-94.
46. Uher R, Payne JL, Pavlova B, Perlis RH. Major depressive disorder in DSM-5: implications for clinical practice and research of changes from DSM-IV. Depression Anxiety 2014;31:459-71.
47. Willner P. Chronicmild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology 2005;52:90-110.
48. Wong ML, Licinio J. Research and treatment approaches to depression. Nat Rev Neurosci 2001;2:343-51.
49. Wu TC, Chen HT, Chang HY, Yang CY, Hsiao MC, Cheng ML, et al. Mineralocorticoid receptor antagonist spironolactone prevents chronic corticosterone induced depression-like behavior. Psychoneuroendocrinology 2013;38:871-83.
50. Zhao Y, Ma R, Shen J, Su H, Xing D, Du L. Amousemodel of depression induced by repeated corticosterone injections. Eur J Pharmacol 2008;581:113-20.